MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
MGTX stock logo

MGTX

MeiraGTx Holdings plc

$9.21
0.12
 (1.32%)
Exchange:  NASDAQ
Market Cap:  852.933M
Shares Outstanding:  37.724M
Delayed data
Calculate MGTX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Alexandria Forbes
Full Time Employees:  375
Address: 
430 East 29th Street
New York City
NY
10016
US
Website:  https://www.meiragtx.com
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson’s. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren’s syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx’s proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue14,01733,27981,391
Gross Profit14,0179,48876,548
EBITDA-57,052-121,691-105,968
Operating Income-137,061-164,212-105,968
Net Income-84,027-147,791-114,201

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets326,744269,751244,430
Total Liabilities188,567201,924250,223
Total Stockholders Equity138,17767,827-5,793
Total Debt89,26484,79714,349
Cash and Cash Equivalents129,566103,65965,931

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-105,365-104,495-46,359
Capital Expenditure-20,174-4,955-3,826
Free Cash Flow-125,539-109,450-50,185
Net Income-84,027-147,791-114,201
Net Change in Cash15,133-24,981-37,475

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)27,949.195Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,605,191.747Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)557,774Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-1,605,191.747Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-27,949.195Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-557,774Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-20,401.116Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)298,919.594Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)86,864.601Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)54,433.078Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,126,227.020Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,086,305.205Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.080Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)3.720Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-0.250Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
33.279M  ?P/S
 (TTM)
: 
10.45
?Net Income
 (TTM)
: 
-147791000  ?P/E
 (TTM)
: 
-6.07
?Enterprise Value
 (TTM)
: 
849.478M  ?EV/FCF
 (TTM)
: 
-362.56
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
4.75  ?ROIC
 (TTM)
: 
-1.1
?Net Debt
 (TTM)
: 
-18862000  ?Debt/Equity
 (TTM)
: 
-1.51
?P/B
 (TTM)
: 
-12.59  ?Current Ratio
 (TTM)
: 
0.55

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about MGTX valuation

Is MeiraGTx Holdings plc (MGTX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for MeiraGTx Holdings plc (MGTX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is MGTX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MGTX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is MGTX’s P/E ratio?

You can see MGTX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for MGTX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is MGTX a good long-term investment?

Whether MGTX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

MGTX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.32
MARKETSnap

Trading Metrics:

Open: 9.27   Previous Close: 9.09
Day Low: 8.89   Day High: 9.49
Year Low: 6.07   Year High: 11.85
Price Avg 50: 9.54   Price Avg 200: 8.32
Volume: 570969   Average Volume: 820634

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
05-06-2026 16:32
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
15-05-2026 04:30
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14-05-2026 16:30
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
14-05-2026 10:10
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
16-04-2026 17:01
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
MeiraGTx: Turning Dry Mouth Into Liquid Gold
15-04-2026 13:26
MeiraGTx: Turning Dry Mouth Into Liquid Gold

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read